Seroquel Approvable Letter
October 30 2003 - 8:00AM
UK Regulatory
RNS Number:4850R
AstraZeneca PLC
30 October 2003
Stock Exchange Announcement
ASTRAZENECA RECEIVES FDA APPROVABLE LETTER FOR SEROQUELTM (QUETIAPINE FUMARATE)
TABLETS
IN TREATMENT OF MANIA
AstraZeneca today announced that it has received an approvable letter from the
U.S. Food and Drug Administration (FDA) in response to its Supplemental New Drug
Applications (sNDAs) for the use of SEROQUEL as both an adjunct and monotherapy
for the treatment of manic episodes associated with bipolar disorder. The
company is working closely with the FDA to supply information and to finalize
labelling.
-Ends-
30th October, 2003
Media Enquiries:
Chris Major, +44 (0) 207 304 5028
Investor Enquiries:
Mina Blair-Robinson, +44 (0) 207 304 5084
Jonathan Hunt, +44 (0) 207 304 5087
This information is provided by RNS
The company news service from the London Stock Exchange
END
REAURVAROWRROAA